FibroBiologics Inc. (NASDAQ:FBLG) Short Interest Down 58.9% in January

FibroBiologics Inc. (NASDAQ:FBLG) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 372,855 shares, a decline of 58.9% from the December 31st total of 907,076 shares. Based on an average trading volume of 2,493,848 shares, the short-interest ratio is currently 0.1 days. Approximately 0.6% of the company’s shares are short sold. Approximately 0.6% of the company’s shares are short sold. Based on an average trading volume of 2,493,848 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

A number of equities analysts have commented on FBLG shares. HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of FibroBiologics in a report on Friday, January 2nd. D. Boral Capital restated a “buy” rating and set a $15.00 target price on shares of FibroBiologics in a research note on Tuesday, January 6th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, FibroBiologics presently has an average rating of “Hold” and an average target price of $10.00.

Insider Buying and Selling

In related news, General Counsel Ruben A. Garcia acquired 140,000 shares of the stock in a transaction that occurred on Thursday, December 11th. The shares were bought at an average price of $0.34 per share, for a total transaction of $47,600.00. Following the completion of the transaction, the general counsel directly owned 140,000 shares in the company, valued at approximately $47,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.00% of the stock is owned by insiders.

Institutional Investors Weigh In On FibroBiologics

Several hedge funds have recently added to or reduced their stakes in the business. Yorkville Advisors Global LP purchased a new stake in shares of FibroBiologics in the third quarter worth about $278,000. Landscape Capital Management L.L.C. bought a new position in shares of FibroBiologics during the third quarter valued at approximately $191,000. Cascade Financial Partners LLC boosted its position in shares of FibroBiologics by 11.7% during the second quarter. Cascade Financial Partners LLC now owns 290,581 shares of the company’s stock valued at $181,000 after buying an additional 30,500 shares during the last quarter. AMG National Trust Bank purchased a new position in shares of FibroBiologics in the fourth quarter worth approximately $31,000. Finally, Cerity Partners LLC boosted its stake in shares of FibroBiologics by 37.2% in the second quarter. Cerity Partners LLC now owns 128,109 shares of the company’s stock worth $80,000 after acquiring an additional 34,702 shares during the period.

FibroBiologics Stock Down 2.8%

NASDAQ:FBLG traded down $0.01 during trading hours on Friday, reaching $0.33. 508,378 shares of the company’s stock were exchanged, compared to its average volume of 1,579,030. FibroBiologics has a 12 month low of $0.22 and a 12 month high of $2.00. The company has a market capitalization of $22.07 million, a P/E ratio of -0.69 and a beta of -0.54. The business’s 50-day simple moving average is $0.30 and its two-hundred day simple moving average is $0.44.

FibroBiologics (NASDAQ:FBLG) last announced its quarterly earnings data on Friday, October 31st. The company reported ($0.13) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.03). As a group, sell-side analysts anticipate that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.